2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Conditions
Leukemia, Myeloid, Acute
84
Leukemia
32
Myelodysplastic Syndromes
19
Leukemia, Myelomonocytic, Acute
14
Leukemia, Monocytic, Acute
14
Leukemia, Erythroblastic, Acute
14
Leukemia, Megakaryoblastic, Acute
13
Congenital Abnormalities
13
Leukemia, Promyelocytic, Acute
7
Recurrence
6
Anemia, Refractory, with Excess of Blasts
6
Leukemia, Eosinophilic, Acute
5
Leukemia, Basophilic, Acute
5
Leukemia, Myelomonocytic, Chronic
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasm, Residual
2
Myeloproliferative Disorders
2
Leukemia, Myelomonocytic, Juvenile
2
Sarcoma, Myeloid
1
Leukemia, Myeloid
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Disease Progression
1
Disease
1
Blast Crisis
1
Interventions
Cyclophosphamide
23
blinatumomab
18
Cytarabine
16
fludarabine
13
Azacitidine
12
venetoclax
10
fludarabine phosphate
10
Rituximab
8
Blood Specimen Collection
8
Methotrexate
7
Lenalidomide
7
Dexamethasone
7
Daunorubicin
7
Mercaptopurine
6
Vincristine
5
daratumumab
4
Whole-Body Irradiation
4
Melphalan
4
Idarubicin
4
Etoposide
4
Drug Therapy
4
Busulfan
4
pembrolizumab
3
obinutuzumab
3
Radiotherapy
3
Neoadjuvant Therapy
3
Maintenance
3
Liquid Biopsy
3
Immunotherapy, Adoptive
3
Imatinib Mesylate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
Gemtuzumab
×
Clear all
NCT05904106
2024-12-02
VINCENT
Technische Universität Dresden
Phase 2
Recruiting
146 enrolled
NCT02724163
2021-10-08
Myechild01
University of Birmingham
Phase 3
Recruiting
700 enrolled